Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 882370 |
| Synonyms | |
| Therapy Description |
BI 882370 is a Raf kinase inhibitor with potent activity against the inactive conformation of Braf and may result in tumor regression (PMID: 26916115). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 882370 | XP-102|BI-882370|BI882370|XP 102|XP102 | BRAF Inhibitor 26 RAF Inhibitor (Pan) 29 | BI 882370 is a Raf kinase inhibitor with potent activity against the inactive conformation of Braf and may result in tumor regression (PMID: 26916115). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 |